#ctor

@bibliotecahuvh.bsky.social

4 days ago

Totally robotic lung transplant: A novel approach Lung transplantation is a highly complex surgical technique used for the treatment of end-stage lung diseases that must meet a precise requirement. Li…

Chapter 32 - Totally robotic lung transplant: A novel approach www.sciencedirect.com/science/chap... #hvhebron #ctor

@bibliotecahuvh.bsky.social

2 months ago

An international perspective on allocation rules for combined heart-lung transplantation While the global numbers of lung transplants have increased, the annual numbers of heart-lung transplants have steadily declined over the last decades…

An international perspective on allocation rules for combined heart-lung transplantation www.sciencedirect.com/science/arti... #hvhebron #ctor #tras [Text complet]

StockTitan

@stocktitan.net

2 months ago

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025. Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct offering on December 10, 2025, to strengthen cash position and support continued commercialization of LYMPHIR. With the U.S. commercial launch of LYMPHIR now...

#CTOR #CTXR Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTOR/citius-oncolog...

StockTitan

@stocktitan.net

2 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025. CRANFORD, N.J., Dec. 23, 2025/ PRNewswire/-- Citius Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal year...

#CTOR #CTXR Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTOR/citius-pharmac...

StockTitan

@stocktitan.net

3 months ago

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim Citius Oncology (Nasdaq: CTOR) announced on December 4, 2025 an exclusive distribution agreement with Er-Kim to commercialize LYMPHIR (denileukin diftitox-cxdl) in Turkey and Gulf Cooperation Council countries: Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the United Arab Emirates.The partnership expands LYMPHIR international availability to 19 markets outside the U.S., using Named Patient Programs where permitted by local law. LYMPHIR is an FDA-approved IL-2 receptor-directed cytotoxin for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. Under the agreement, Er-Kim will handle sales, marketing and reimbursement while Citius Oncology supplies finished product and provides support.

#CTOR #CTXR Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

www.stocktitan.net/news/CTOR/citius-oncolog...

@bibliotecahuvh.bsky.social

3 months ago

BAP-1 IN THE DIAGNOSIS OF MALIGNANT PLEURAL MESOTHELIOMA The diagnosis of malignant pleural mesothelioma (MPM) can be challenging for clinicians and pathologists.This study included all patients diagnosed wi…

BAP-1 in the diagnosis of malignant pleural mesothelioma www.sciencedirect.com/science/arti... #hvhebron #ctor

StockTitan

@stocktitan.net

3 months ago

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) CRANFORD, N.J., Dec. 1, 2025/ PRNewswire/-- Citius Oncology, Inc., the oncology-focused subsidiary of Citius Pharmaceuticals, Inc., today announced the commercial launch of LYMPHIR™. LYMPHIR is a novel IL-2 receptor-directed fusion protein approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory Stage I– III...

#CTOR #CTXR Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

www.stocktitan.net/news/CTOR/citius-oncolog...

StockTitan

@stocktitan.net

3 months ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch. CRANFORD, N.J., Nov. 21, 2025/ PRNewswire/-- Citius Oncology, Inc., the oncology-focused subsidiary of Citius Pharmaceuticals, Inc., a late-stage biopharmaceutical company...

#CTOR #CTXR Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

www.stocktitan.net/news/CTOR/citius-oncolog...

@bibliotecahuvh.bsky.social

4 months ago

Eculizumab as rescue therapy for antibody-mediated rejection in a high-risk lung transplant recipient: A case report AbstractPurpose. To describe the management of refractory antibody-mediated rejection (AMR) in a highly sensitized lung transplant recipient, emphasizing t

Eculizumab as rescue therapy for antibody-mediated rejection in a high-risk #lung #transplant recipient: A case report academic.oup.com/ajhp/advance... #hvhebron #far #mintens #pneu #nefro #ctor

StockTitan

@stocktitan.net

4 months ago

Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch Citius Oncology (Nasdaq: CTOR) signed a U.S. distribution services agreement with McKesson (NYSE: MCK) to serve as an authorized distributor of record for LYMPHIR (denileukin diftitox-cxdl).LYMPHIR is FDA approved for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. The McKesson agreement completes Citius Oncology's core U.S. distribution network with all three largest pharmaceutical wholesalers, supporting the planned commercial launch in Q4 2025. The company also cites inventory readiness, permanent J-code J9161, NCCN guideline inclusion, and provider and patient education resources as part of its commercialization preparations.

#CTOR #CTXR #MCK Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

www.stocktitan.net/news/CTOR/citius-oncolog...

StockTitan

@stocktitan.net

5 months ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ Citius Oncology (Nasdaq: CTOR) finalized an exclusive Master Service Agreement with EVERSANA to support the planned U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl) in Q4 2025. EVERSANA will provide an integrated suite of pre- and post-launch services including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, and channel management. LYMPHIR was approved by the U.S. FDA in August 2024 for relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. The agreement is exclusive and intended to scale launch operations and market access for LYMPHIR in the United States.

#CTOR #CTXR Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

www.stocktitan.net/news/CTOR/citius-oncolog...

StockTitan

@stocktitan.net

5 months ago

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe Citius Oncology (Nasdaq: CTOR) announced on October 7, 2025 that it is expanding international access to LYMPHIR™ (denileukin diftitox-cxdl) via country-specific Named Patient Programs (NPPs) in Europe, South America and the Middle East.The company signed an exclusive distribution agreement with Integris Pharma S.A., headquartered in Athens, to cover Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro and North Macedonia. NPPs provide early patient access prior to full marketing authorization and do not constitute commercial approval outside the U.S.

#CTOR Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe

www.stocktitan.net/news/CTOR/citius-oncolog...

@bibliotecahuvh.bsky.social

5 months ago

Unlocking the potential of uncontrolled DCD in lung transplantation: A review of 2 decades of experience Uncontrolled donation after circulatory death (uDCD) represents a promising yet underutilized approach to expanding the lung donor pool amid persisten…

Unlocking the potential of uncontrolled DCD in lung transplantation: A review of 2 decades of experience www.sciencedirect.com/science/arti... #hvhebron #ctor #mintens #tras [Text complet]

Thiard News@F4F

@newsen.bsky.social

6 months ago

Citius Oncology Completes $9 Million Offering to Boost Oncology Innovations Citius Oncology has successfully closed a $9 million direct offering and private placement to enhance its innovative oncology therapies. The capital raised will support the company's growth.

Citius Oncology Completes $9 Million Offering to Boost Oncology Innovations #United_States #Cranford #LYMPHIR #Citius_Oncology #CTOR

@bibliotecahuvh.bsky.social

6 months ago

Unlocking the Potential of Uncontrolled DCD in Lung Transplantation: A Review of Two Decades of Experience Uncontrolled donation after circulatory death (uDCD) represents a promising yet underutilized approach to expanding the lung donor pool amid persisten…

Unlocking the Potential of Uncontrolled DCD in Lung Transplantation: A Review of Two Decades of Experience www.sciencedirect.com/science/arti... #hvhebron #ctor #tras #mintens [Text complet]

StockTitan

@stocktitan.net

6 months ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch Citius Oncology (NASDAQ:CTOR) has announced the deployment of a proprietary AI platform to enhance its commercial team's performance ahead of the anticipated LYMPHIR™ launch for cutaneous T-cell lymphoma (CTCL) treatment. The platform leverages advanced data analytics and machine learning to identify potential LYMPHIR candidates and optimize healthcare provider engagement.The AI system analyzes treatment patterns and diagnosis data to support targeted prescriber outreach. It features a continuous learning model that integrates real-world U.S. claims data and marketing performance analytics to deliver predictive insights and enable personalized customer engagement across digital and in-person channels.

#CTOR #CTXR Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

www.stocktitan.net/news/CTOR/citius-oncolog...

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

SMALL CAP STRATEGIST: Most searched small-cap stocks, Wed Jul 30th - #RIG #DNN #LIDR #HIVE #SAGE #VWAV #SRPT #PTON #FUBO #SBET #REPL #PUMP #OPEN #LUNR #ESPR #CTOR #BYRN #APLD #ALHC - More: crystalequityresearch.com/most-searche... - #smallcap

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Most searched small-cap stocks, Tue Jul 29th - #HIVE #REPL #SBET #FFAI #LIDR #SRPT #DNN #SLDP #TDOC #OPEN #LUNR #IQ #DEFT #CTOR #CERS #BTCS #ATNF #CIFR #ALLO #ALHC - More: crystalequityresearch.com/most-searche... - #smallcap

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

Small-cap stocks with strong volume gains, Wed Jul 16th - #HLLY #PKE #UCL #DPRO #CTOR #BNRG #APM #HYAC #STG #SIFY #GAME #IRIX #KITT #RPTX #QLGN #PPSI #NTWK #MEIP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

8 months ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering Citius Oncology (NASDAQ:CTOR) has announced the pricing of a public offering to raise $9.0 million through the sale of 6,818,182 shares of common stock and warrants at $1.32 per share. The warrants will have the same exercise price, be immediately exercisable, and expire in five years.The company plans to use the proceeds primarily for the commercialization of LYMPHIR, including milestone and royalty payments, as well as working capital. The offering, managed by Maxim Group LLC as sole placement agent, is expected to close around July 17, 2025.

#CTOR #CTXR Citius Oncology Announces Pricing of $9.0 Million Public Offering

www.stocktitan.net/news/CTOR/citius-oncolog...

StockTitan

@stocktitan.net

8 months ago

Citius Oncology Secures Major Distribution Deal for New FDA-Approved Lymphoma Treatment LYMPHIR Citius Oncology teams with Cencora to enhance distribution network for LYMPHIR, its FDA-approved immunotherapy for CTCL. Learn about market expansion strategy.

#CTOR #CTXR Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

www.stocktitan.net/news/CTOR/citius-oncolog...

StockTitan

@stocktitan.net

8 months ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 Citius Oncology (NASDAQ: CTOR) is preparing for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for treating adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), scheduled for the second half of 2025. The company has completed key launch preparations including commercial-scale manufacturing with 60-month shelf life inventory sufficient for 12-18 months post-launch. Distribution agreements with global logistics partners are being finalized to ensure broad U.S. access. The company has garnered significant interest from the medical community, with 70 institutional oncology centers already registered. LYMPHIR has secured NCCN guideline inclusion and a permanent J-code, positioning it well for reimbursement. The recent capital raise by parent company Citius Pharma (NASDAQ: CTXR) supports the launch, while strategic partnership discussions are ongoing to expand market reach.

#CTOR #CTXR Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

www.stocktitan.net/news/CTOR/citius-oncolog...

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

A close-up of a person's shoulder with dry, peeling skin as a finger gently points to the affected area, representing a dermatological condition.

Big move for #CitiusOncology! #CTOR has partnered with
#cardinalhealth #CAH to support the U.S. launch of LYMPHIR, its FDA-approved therapy for cutaneous T-cell lymphoma (CTCL). Shares surged 30% on the news.

prismmarketview.com/citius-inks-...

StockTitan

@stocktitan.net

9 months ago

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health Citius Oncology (CTOR), a subsidiary of Citius Pharmaceuticals (CTXR), has secured a distribution services agreement with Cardinal Health (CAH) for LYMPHIR, their FDA-approved immunotherapy treatment for relapsed or refractory cutaneous T-cell lymphoma (CTCL) in adults. The partnership positions Cardinal Health as an authorized distributor of record, leveraging their established pharmaceutical distribution network to facilitate LYMPHIR's upcoming U.S. commercial launch. This strategic agreement aims to ensure efficient and reliable delivery of LYMPHIR to healthcare providers and patients, marking a significant milestone in Citius Oncology's launch preparation strategy.

#CTXR #CTOR #CAH Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

www.stocktitan.net/news/CTXR/citius-oncolog...

@bibliotecahuvh.bsky.social

9 months ago

Frontiers | Role of VATS-US in identifying and characterizing pulmonary nodules: a narrative review The aim of this study was to show the efficacy described in the scientific literature of lung ultrasound (LU) during video-assisted thoracic surgery (VATS) t...

Role of VATS-US in identifying and characterizing pulmonary nodules: a narrative review www.frontiersin.org/journals/sur... #hvhebron #cardio #anest #ctor [Text complet]

StockTitan

@stocktitan.net

10 months ago

Citius Oncology Reports Critical Cash Position with Only $112M Left After FDA Win Q2 losses surge 60% to $7.7M as Citius prepares LYMPHIR commercial launch. Company exploring strategic alternatives amid May 2025 cash runway. See full details.

#CTOR Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CTOR/citius-oncolog...

@bibliotecahuvh.bsky.social

10 months ago

Investigating Factors Influencing Baseline Allograft Dysfunction in Patients Undergoing Bilateral Lung Transplantation Purpose: Baseline Lung Allograft Dysfunction (BLAD) occurs when normal lung function (FEV1 and FVC > 80%) is not achieved after lung transplantation (LT). This study evaluates the association of pre- ...

Investigating Factors Influencing Baseline Allograft Dysfunction in Patients Undergoing Bilateral Lung Transplantation www.jhltonline.org/article/S105... #hvhebron #pneu #mintens #ctor

@bibliotecahuvh.bsky.social

10 months ago

Long-Term Results of Segmentectomy vs. Lobectomy for c-Stage IA Lung Cancer: A Real-Life Study with a Propensity Score Analysis Based on a National Cohort www.mdpi.com/2077-0383/14... #hvhebron #ctor [Text complet]